Radius Health, Inc. (RDUS) Announces Positive Results of Phase 3 ACTIVE Trial Published in JAMA
Radius Health, Inc. (NASDAQ: RDUS), a biopharmaceutical company committed to developing unique therapeutics in osteoporosis, oncology, and endocrine diseases, recently announced that the positive results of it phase 3 ACTIVE trial were published in the Journal of the American Medical Association (JAMA). ACTIVE stands for Abaloparatide Comparator Trial InVertebral Endpoints. Abaloparatide is a drug being trialed for the treatment of postmenopausal women with osteoporosis. The trial involved 2,463 patients and was put in place to establish whether or not the drug was both safe and efficient. In a news release, Dr. Paul Miller, medical director of the Colorado Center for…







